​

Repare Therapeutics (RPTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

RPTX Stock Forecast

Repare Therapeutics stock forecast is as follows: an average price target of $10.00 (represents a 640.74% upside from RPTX’s last price of $1.35) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

RPTX Price Target

The average price target for Repare Therapeutics (RPTX) is $10.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $10.00. This represents a potential 640.74% upside from RPTX's last price of $1.35.

RPTX Analyst Ratings

Buy

According to 5 Wall Street analysts, Repare Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for RPTX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Repare Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 04, 2024Robert BurnsH.C. Wainwright$10.00$2.81255.87%640.74%
Feb 03, 2023Morgan Stanley$15.00$13.1414.16%1011.11%
Nov 17, 2022H.C. Wainwright$25.00$17.0047.06%1751.85%
Jun 20, 2022Joseph CatanzaroPiper Sandler$30.00$13.27126.07%2122.22%

The latest Repare Therapeutics stock forecast, released on Sep 04, 2024 by Robert Burns from H.C. Wainwright, set a price target of $10.00, which represents a 255.87% increase from the stock price at the time of the forecast ($2.81), and a 640.74% increase from RPTX last price ($1.35).

Repare Therapeutics Price Target by Period

1M3M12M
# Anlaysts--1
Avg Price Target--$10.00
Last Closing Price$1.35$1.35$1.35
Upside/Downside-100.00%-100.00%640.74%

In the current month, the average price target of Repare Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Repare Therapeutics's last price of $1.35. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Sep 16, 2024Piper SandlerOverweightOverweightHold
Sep 04, 2024H.C. WainwrightBuyBuyHold
Jun 09, 2023DaiwaBuyUpgrade
Feb 03, 2023Morgan StanleyEqual-WeightDowngrade
Jun 20, 2022Piper SandlerOverweightOverweightHold
Jun 02, 2022Roth CapitalBuyInitialise

Repare Therapeutics's last stock rating was published by Piper Sandler on Sep 16, 2024. The company gave RPTX a "Overweight" rating, the same as its previous rate.

Repare Therapeutics Financial Forecast

Repare Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
Revenue-----------$5.68M$18.20M$112.55M$679.00K$408.00K$6.88M$278.00K$279.00K$166.00K$135.00K-
Avg Forecast$2.92M$2.34M$2.34M$2.34M$2.73M$2.73M$2.92M$38.40M$18.93M$6.31M$7.01M$5.14M$9.72M$1.98M$5.43M$2.35M$3.82M$244.75K$1.00M$1.25M$2.50M$1.25M
High Forecast$3.75M$3.00M$3.00M$3.00M$4.63M$2.82M$2.92M$49.23M$65.40M$6.31M$8.99M$6.60M$12.46M$1.98M$5.43M$2.35M$3.82M$244.75K$1.00M$1.25M$2.50M$1.25M
Low Forecast$1.50M$1.20M$1.20M$1.20M$1.02M$2.64M$2.92M$19.69M$2.97M$6.31M$3.60M$2.64M$4.98M$1.98M$5.43M$2.35M$3.82M$244.75K$1.00M$1.25M$2.50M$1.25M
# Analysts1114424454443333444444
Surprise %-----------1.10%1.87%56.98%0.13%0.17%1.80%1.14%0.28%0.13%0.05%-

Repare Therapeutics's average Quarter revenue forecast for Jun 23 based on 4 analysts is $7.01M, with a low forecast of $3.60M, and a high forecast of $8.99M. RPTX's average Quarter revenue forecast represents a 23.53% increase compared to the company's last Quarter revenue of $5.68M (Mar 23).

Repare Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts1114424454443333444444
EBITDA---------$-38.42M$-12.26M$-34.63M$-19.23M$73.76M$-38.35M$-34.30M$-28.23M$-31.18M$-26.28M$-21.17M$-16.45M$-13.28M
Avg Forecast$-1.25M$-999.25K$-999.25K$-999.25K$-1.17M$-1.17M$-1.25M$-16.40M$-8.08M$-2.69M$-3.00M$-2.20M$-4.15M$-850.24K$-2.34M$-35.40M$-1.65M$-105.36K$-430.50K$-18.26M$-1.08M$-538.12K
High Forecast$-640.55K$-512.44K$-512.44K$-512.44K$-434.72K$-1.13M$-1.25M$-8.41M$-1.27M$-2.69M$-1.54M$-1.13M$-2.13M$-850.24K$-2.34M$-28.32M$-1.65M$-105.36K$-430.50K$-14.61M$-1.08M$-538.12K
Low Forecast$-1.60M$-1.28M$-1.28M$-1.28M$-1.98M$-1.21M$-1.25M$-21.02M$-27.93M$-2.69M$-3.84M$-2.82M$-5.32M$-850.24K$-2.34M$-42.48M$-1.65M$-105.36K$-430.50K$-21.92M$-1.08M$-538.12K
Surprise %---------14.26%4.09%15.76%4.64%-86.75%16.41%0.97%17.15%295.91%61.05%1.16%15.28%24.68%

3 analysts predict RPTX's average Quarter EBITDA for Dec 22 to be $-4.15M, with a high of $-2.13M and a low of $-5.32M. This is -105.63% lower than Repare Therapeutics's previous annual EBITDA (Sep 22) of $73.76M.

Repare Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts1114424454443333444444
Net Income---------$-51.48M$-11.95M$-34.94M$-31.66M$75.46M$-38.09M$-34.76M$-28.29M$-30.89M$-26.31M$-21.42M$-15.26M$-13.75M
Avg Forecast$-32.02M$-29.88M$-29.74M$-31.21M$-35.21M$-36.98M$-36.88M$667.10K$-15.22M$-36.46M$-34.28M$-34.33M$-30.09M$909.56K$-33.05M$-35.97M$-31.41M$-30.14M$-25.68M$-18.48M$-16.81M$-16.06M
High Forecast$-11.74M$-10.96M$-10.90M$-28.92M$-30.96M$-13.56M$-13.52M$673.17K$7.88M$-13.37M$-12.57M$-12.59M$-11.03M$909.56K$-33.05M$-28.78M$-31.41M$-30.14M$-25.68M$-14.78M$-16.81M$-16.06M
Low Forecast$-43.76M$-40.84M$-40.64M$-33.87M$-44.54M$-50.53M$-50.40M$661.03K$-24.19M$-49.82M$-46.85M$-46.91M$-41.12M$909.56K$-33.05M$-43.16M$-31.41M$-30.14M$-25.68M$-22.17M$-16.81M$-16.06M
Surprise %---------1.41%0.35%1.02%1.05%82.96%1.15%0.97%0.90%1.03%1.02%1.16%0.91%0.86%

Repare Therapeutics's average Quarter net income forecast for Dec 22 is $-30.09M, with a range of $-41.12M to $-11.03M. RPTX's average Quarter net income forecast represents a -139.87% decrease compared to the company's last Quarter net income of $75.46M (Sep 22).

Repare Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts1114424454443333444444
SG&A---------$7.87M$8.72M$8.53M$7.94M$7.90M$7.94M$8.78M$7.64M$6.60M$6.74M$5.24M$4.79M$4.00M
Avg Forecast$65.30M$52.24M$52.24M$52.24M$61.02M$61.02M$65.29M$857.27M$422.62M$140.87M$156.59M$114.85M$216.92M$44.09M$121.22M$52.50M$85.35M$5.46M$22.32M$27.91M$55.81M$27.91M
High Forecast$83.72M$66.97M$66.97M$66.97M$103.41M$63.04M$65.30M$1.10B$1.46B$140.87M$200.76M$147.24M$278.10M$44.09M$121.22M$52.50M$85.35M$5.46M$22.32M$27.91M$55.81M$27.91M
Low Forecast$33.49M$26.79M$26.79M$26.79M$22.73M$59.00M$65.29M$439.62M$66.37M$140.87M$80.30M$58.90M$111.24M$44.09M$121.22M$52.50M$85.35M$5.46M$22.32M$27.91M$55.81M$27.91M
Surprise %---------0.06%0.06%0.07%0.04%0.18%0.07%0.17%0.09%1.21%0.30%0.19%0.09%0.14%

Repare Therapeutics's average Quarter SG&A projection for Dec 23 is $422.62M, based on 5 Wall Street analysts, with a range of $66.37M to $1.46B. The forecast indicates a 5271.33% rise compared to RPTX last annual SG&A of $7.87M (Sep 23).

Repare Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts1114424454443333444444
EPS---------$-1.22$-0.28$-0.83$-0.76$1.80$-0.91$-0.83$-0.70$-0.83$-0.71$-0.58$-0.41$-0.37
Avg Forecast$-0.75$-0.70$-0.70$-0.74$-0.83$-0.87$-0.87$0.02$-0.36$-0.86$-0.81$-0.81$-0.71$0.02$-0.78$-0.86$-0.74$-0.71$-0.60$-0.51$-0.40$-0.38
High Forecast$-0.28$-0.26$-0.26$-0.68$-0.73$-0.32$-0.32$0.02$0.19$-0.31$-0.30$-0.30$-0.26$0.02$-0.78$-0.86$-0.74$-0.71$-0.60$-0.51$-0.40$-0.38
Low Forecast$-1.03$-0.96$-0.96$-0.80$-1.05$-1.19$-1.19$0.02$-0.57$-1.17$-1.10$-1.11$-0.97$0.02$-0.78$-0.86$-0.74$-0.71$-0.60$-0.51$-0.40$-0.38
Surprise %---------1.42%0.35%1.03%1.07%84.00%1.17%0.97%0.95%1.17%1.17%1.15%1.04%0.98%

According to 3 Wall Street analysts, Repare Therapeutics's projected average Quarter EPS for Dec 22 is $-0.71, with a low estimate of $-0.97 and a high estimate of $-0.26. This represents a -139.38% decrease compared to RPTX previous annual EPS of $1.80 (Sep 22).

Repare Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
RPTXRepare Therapeutics$1.46$10.00584.93%Buy
RLAYRelay Therapeutics$4.50$18.00300.00%Buy
ACCDAccolade$3.40$8.08137.65%Buy
NRIXNurix Therapeutics$21.18$32.6754.25%Buy

RPTX Forecast FAQ

Is Repare Therapeutics a good buy?

Yes, according to 5 Wall Street analysts, Repare Therapeutics (RPTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of RPTX's total ratings.

What is RPTX's price target?

Repare Therapeutics (RPTX) average price target is $10 with a range of $10 to $10, implying a 640.74% from its last price of $1.35. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Repare Therapeutics stock go up soon?

According to Wall Street analysts' prediction for RPTX stock, the company can go up by 640.74% (from the last price of $1.35 to the average price target of $10), up by 640.74% based on the highest stock price target, and up by 640.74% based on the lowest stock price target.

Can Repare Therapeutics stock reach $2?

RPTX's average twelve months analyst stock price target of $10 supports the claim that Repare Therapeutics can reach $2 in the near future.

What are Repare Therapeutics's analysts' financial forecasts?

Repare Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $46.79M (high $59.61M, low $26.28M), average EBITDA is $-19.981M (high $-11.221M, low $-25.456M), average net income is $-108M (high $-57.37M, low $-145M), average SG&A $1.04B (high $1.33B, low $586.64M), and average EPS is $-2.553 (high $-1.351, low $-3.411). RPTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $9.94M (high $12.75M, low $5.1M), average EBITDA is $-4.247M (high $-2.178M, low $-5.445M), average net income is $-123M (high $-62.523M, low $-159M), average SG&A $222.02M (high $284.64M, low $113.86M), and average EPS is $-2.894 (high $-1.473, low $-3.748).

Did the RPTX's actual financial results beat the analysts' financial forecasts?

Based on Repare Therapeutics's last annual report (Dec 2022), the company's revenue was $131.83M, beating the average analysts forecast of $19.47M by 576.98%. Apple's EBITDA was $-20.104M, missing the average prediction of $-42.74M by -52.96%. The company's net income was $-29.047M, missing the average estimation of $-98.195M by -70.42%. Apple's SG&A was $32.56M, missing the average forecast of $434.73M by -92.51%. Lastly, the company's EPS was $-0.69, missing the average prediction of $-2.322 by -70.28%. In terms of the last quarterly report (Mar 2023), Repare Therapeutics's revenue was $5.68M, beating the average analysts' forecast of $5.14M by 10.37%. The company's EBITDA was $-34.625M, beating the average prediction of $-2.197M by 1476.11%. Repare Therapeutics's net income was $-34.941M, beating the average estimation of $-34.326M by 1.79%. The company's SG&A was $8.53M, missing the average forecast of $114.85M by -92.57%. Lastly, the company's EPS was $-0.83, beating the average prediction of $-0.809 by 2.65%